NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

With an annual revenue of $60 million, the company could finally turn to revenues to meet their receivables. With that, there'd be no more dilution to fund the business, so tapping long shareholders would minimally go on the back burner.

And IF (notice the big "if") there were entities or an entity out there that had intent on the ruination of NWBO, that goal would certainly become much more difficult because this would be a biotech that was finally taking in actual real, relevant revenue.

Combine that with TLD by hopefully end of June, and it looks like LP and other's warrant restriction would have value. But of course, as you state, that value is contingent, for now, on a significant rise in share price over the next 6 months.